The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Calcium-Channel Blocker–Clarithromycin Drug Interactions and Acute Kidney Injury
Abstract
IMPORTANCE: Calcium-channel blockers are metabolized by the cytochrome P450 3A4 (CYP3A4; EC 1.14.13.97) enzyme. Blood concentrations of these drugs may rise to harmful levels when CYP3A4 activity is inhibited. Clarithromycin is an inhibitor of CYP3A4 and azithromycin is not, which makes comparisons between these 2 macrolide antibiotics useful in assessing clinically important drug interactions. OBJECTIVE: To characterize the risk of acute adverse events following coprescription of clarithromycin compared with azithromycin in older adults taking a calcium-channel blocker. DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study in Ontario, Canada, from 2003 through 2012 of older adults (mean age, 76 years) who were newly coprescribed clarithromycin (n = 96,226) or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedipine, diltiazem, or verapamil). MAIN OUTCOMES AND MEASURES: Hospitalization with acute kidney injury (primary outcome) and hospitalization with hypotension and all-cause mortality (secondary outcomes examined separately). Outcomes were assessed within 30 days of a new coprescription. RESULTS: There were no differences in measured baseline characteristics between the clarithromycin and azithromycin groups. Amlodipine was the most commonly prescribed calcium-channel blocker (more than 50% of patients). Coprescribing clarithromycin vs azithromycin with a calcium-channel blocker was associated with a higher risk of hospitalization with acute kidney injury (420 patients of 96,226 taking clarithromycin [0.44%] vs 208 patients of 94,083 taking azithromycin [0.22%]; absolute risk increase, 0.22% [95% CI, 0.16%-0.27%]; odds ratio [OR], 1.98 [95% CI, 1.68-2.34]). In a subgroup analysis, the risk was highest with dihydropyridines, particularly nifedipine (OR, 5.33 [95% CI, 3.39-8.38]; absolute risk increase, 0.63% [95% CI, 0.49%-0.78%]). Coprescription with clarithromycin was also associated with a higher risk of hospitalization with hypotension (111 patients of 96,226 taking clarithromycin [0.12%] vs 68 patients of 94,083 taking azithromycin [0.07%]; absolute risk increase, 0.04% [95% CI, 0.02%-0.07%]; OR, 1.60 [95% CI, 1.18-2.16]) and all-cause mortality (984 patients of 96,226 taking clarithromycin [1.02%] vs 555 patients of 94,083 taking azithromycin [0.59%]; absolute risk increase, 0.43% [95% CI, 0.35%-0.51%]; OR, 1.74 [95% CI, 1.57-1.93]). CONCLUSIONS AND RELEVANCE: Among older adults taking a calcium-channel blocker, concurrent use of clarithromycin compared with azithromycin was associated with a small but statistically significant greater 30-day risk of hospitalization with acute kidney injury. These findings support current safety warnings regarding concurrent use of CYP3A4 inhibitors and calcium-channel blockers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
Self-citation
Cited by
Efflux pump inhibitors for bacterial pathogens: From bench to bedside
Sharma, A., Gupta, V. K., & Pathania, R. (2019) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_2079_17 · Cited by 458
The growth of acute kidney injury: a rising tide or just closer attention to detail?
Siew, E. D., & Davenport, A. (2015) · Kidney International · doi:10.1038/ki.2014.293 · Cited by 275
Hwang, Y. J., Dixon, S. N., Reiss, J. P., Wald, R., Parikh, C. R., Gandhi, S., Shariff, S. Z., Pannu, N., Nash, D. M., Rehman, F., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2796 · Cited by 136
Self-citationMehrabadi, A., Liu, S., Bartholomew, S., Hutcheon, J. A., Magee, L. A., Kramer, M. S., Liston, R. M., Joseph, K. S., & for the Canadian Perinatal Surveillance System (Public Health Agency of Canada) (2014) · BMJ · doi:10.1136/bmj.g4731 · Cited by 121
Common Drug Side Effects and Drug-Drug Interactions in Elderly Adults in Primary Care
Merel, S. E., & Paauw, D. S. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14870 · Cited by 48
Metadata
- Authors
- Gandhi, S., Fleet, J. L., Bailey, D. G., McArthur, E., Wald, R., Rehman, F., & Garg, A. X.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-12-18
- Volume
- 310
- Issue
- 23
- Pages
- 2544
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2141840620
- Cited by
- 161
- References
- 3
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calcium-Channel Blocker–Clarithromycin Drug Interactions and Acute Kidney Injury. https://app.cochat.ai/papers/10.1001/jama.2013.282426
- The paper
- Gandhi, S., Fleet, J. L., Bailey, D. G., McArthur, E., Wald, R., Rehman, F., & Garg, A. X. (2013). Calcium-Channel Blocker–Clarithromycin Drug Interactions and Acute Kidney Injury. JAMA. https://doi.org/10.1001/jama.2013.282426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.